---
title: "AstraZeneca PLC (AZN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AZN.US.md"
symbol: "AZN.US"
name: "AstraZeneca PLC"
industry: "Pharmaceuticals"
datetime: "2026-05-19T18:17:53.627Z"
locales:
  - [en](https://longbridge.com/en/quote/AZN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AZN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AZN.US.md)
---

# AstraZeneca PLC (AZN.US)

## Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.astrazeneca.com](https://www.astrazeneca.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:14.000Z

**Overall: B (0.37)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 5 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.93% |  |
| Net Profit YoY | 33.67% |  |
| P/B Ratio | 6.03 |  |
| Dividend Ratio | 1.74% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 285249733039.04 |  |
| Revenue | 60439000000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 23.51% | A |
| Profit Margin | 17.19% | A |
| Gross Margin | 82.52% | A |
| Revenue YoY | 9.93% | B |
| Net Profit YoY | 33.67% | B |
| Total Assets YoY | 7.31% | B |
| Net Assets YoY | 15.20% | B |
| Cash Flow Margin | 136.89% | B |
| OCF YoY | 9.93% | B |
| Turnover | 0.55 | C |
| Gearing Ratio | 58.44% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AstraZeneca PLC",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.93%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "33.67%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.03",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.74%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "285249733039.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "60439000000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "23.51%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "17.19%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "82.52%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "9.93%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "33.67%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.31%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "15.20%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "136.89%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "9.93%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "58.44%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 27.46 | 44/190 | 30.90 | 29.71 | 28.12 |
| PB | 6.03 | 157/190 | 6.29 | 5.94 | 5.38 |
| PS (TTM) | 4.72 | 96/190 | 5.04 | 4.69 | 4.11 |
| Dividend Yield | 1.74% | 23/190 | 2.07% | 1.75% | 1.65% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 70% |
| Overweight | 2 | 20% |
| Hold | 1 | 10% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 66.55 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/AZN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/AZN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/AZN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/AZN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**